WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous close | 12.800 |
| Open | 12.900 |
| Bid | 12.980 x 0 |
| Ask | 13.000 x 0 |
| Day's range | 12.740 - 13.340 |
| 52-week range | 12.420 - 52.450 |
| Volume | |
| Avg. volume | 68,848,127 |
| Market cap | 54.056B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 15.27 |
| EPS (TTM) | 0.850 |
| Earnings date | 26 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.08 |
PR NewswireWuXi Biologics Reports Solid 2023 Annual Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").
PR NewswireWuXi Biologics Named to CDP 'A List' for Water Security
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.
PR NewswireWuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environmental non-profit CDP, achieving the Leadership level with a score of "A-".
